However, the outcome of MM patients with Daratumumab is uncertain, partly due to its confounding effects on NK cell lines, such as the clearance of CD38high NK cells and ADCC mainly mediated by NK cells with low or no CD38 membrane expression. This evidence concerns the gene CD38 and Miyoshi myopathy.